Latest "Oxford Therapeutics Consulting Limited" News Stories

13:11 EST 18th December 2017 | BioPortfolio

Here are the most relevant search results for "Oxford Therapeutics Consulting Limited" found in our extensive news archives from over 250 global news sources.

More Information about Oxford Therapeutics Consulting Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Oxford Therapeutics Consulting Limited for you to read. Along with our medical data and news we also list Oxford Therapeutics Consulting Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Oxford Therapeutics Consulting Limited Companies for you to search.

Showing "Oxford Therapeutics Consulting Limited" News Articles 1–25 of 9,700+


Appointment of Director

Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine Soden as non-executive director, and the retirement of Brad Hoy who has served on the e-Therapeutics Board as a non-executive director for nine years.  Christine will take over from Brad Hoy as ...

Oxford mothers-to-be learn about gestational diabetes research

Oxford researchers have attended two events in Oxford to let pregnant women know how to have a healthy pregnancy and to ask them to get involved in giving their views on future research. The researchers from the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust attended two expectant parent events at Mothercare ... Read more

Nightstar gets rights to preclinical ophthalmic program from Oxford University Innovation

Oxford University Innovation Ltd. licensed Nightstar Therapeutics Ltd. exclusive worldwide rights to a preclinical gene thera...

Oxford BioMedica in Second CART Deal with Novartis

UK biopharma Oxford BioMedica has signed another major deal with Swiss drugmaker Novartis to supply lentiviral vectors used to create novel cell therapeutics, including CTL019 (tisagenlecleucel) and other undisclosed Chimeric Antigen Receptor T-cell (CART) products.

Oxford BioMedica: Vector Value: An Interview with Nick Woolf, SVP Corporate Strategy

Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrated specialty pharmaceutical company. They review the company’s history and the finances that have been raised since its successful public listing on AIM in 1996. Together, they discuss the challenges...

Adaptimmune Therapeutics plc: Adaptimmune marks Official Opening of U.K. Headquarters

Flagship Facility is new Base for U.K. Research and Development OperationsPHILADELPHIA and OXFORD, U.K., 2017-11-06 14:14 CET (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leade...

Pivot Point Consulting Announces Zack Tisch as Consulting Services Executive

NASHVILLE, Tenn. (PRWEB) August 22, 2017 Pivot Point Consulting, a Vaco Company, is pleased to announce the addition of Zack Tisch as the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of consulting services for the KLAS-ranked healthcare IT consulting firm’s...

Oxford Immunotec: Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit

Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation OXF...

New light on the secret life of badgers

(University of Oxford) Badgers are more sociable than often thought, with implications for how they transmit disease, new Oxford University research reveals. Using security tracking technology more commonly used to protect museum artwork, the Oxford research has revealed fresh insights into the animals' social behavior.

Mayo Clinic, Oxford Announce Transatlantic Partnership for Medical Research, Education and Healthcare

ROCHESTER, Minn.???Mayo Clinic, the University of Oxford, and Oxford University Hospitals NHS Foundation Trust have signed?an agreement to work together, driving advances in medical research and patient care. This agreement will underpin collaboration in all areas of innovation. Mayo Clinic and Oxford will bring together their respective expertise to improve patient care, make scientific?discoveri...

Isis Innovation: How the Oxford Sciences Innovation fund is promoting investment in the Oxfordshire region

Adam Stoten, head of Technology Transfer at Isis Innovation (the technology transfer arm of the University of Oxford) discusses the recent successes of Oxford Sciences Innovation (OSI), a fund comprising six key investors: Invesco Asset Management Limited, IP Group plc, Lansdowne Partners (UK) LLP, Oxford University Endowment Fund, the Wellcome Trust, and Woodford Investment Management LLP.

Oxford Genetics Secures ??7.5 Million Investment

21st August 2017, Oxford Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has announced a 7.5 million investment into its operations in the US and the UK by Mercia Technologies PLC, an existing investor, and Invesco Perpetual. This investment will fund a new office in Boston, US and a...

Ebb Therapeutics™ selects The Copley Consulting Group To Implement Infor CloudSuite Industrial (SyteLine)™ Solution

The CloudSuite Industrial solution will enable Ebb Therapeutics to scale operations rapidly and meet the expanding customer and market demands with an exceptionally high level of quality. WOBURN, Mass. (PRWEB) October 17, 2017 Ebb Therapeutics, the medical device innovator of Ebb Insomnia Therapy, has selected The Copley Consulting Group to facilitate and deploy Infor’s CloudSuite Industrial (S...

Oxford researchers develop new scan to predict stroke

Researchers at the University of Oxford, supported by the NIHR Oxford Biomedical Research Centre, have developed a new type of MRI scan to predict the risk of having a stroke. The non-invasive technique, developed with funding from the British Heart Foundation (BHF), is described in a paper published in the journal JACC: Cardiovascular Imaging. It ... Read more

Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 ...

OXFORD, United Kingdom, Aug. 25, 2017 (GLOBE NEWSWIRE)

Cerenis Therapeutics: Jean-Louis Dasseux

In this episode of PharmaTelevision News Review, Paul Burge talks with Jean-Louis Dasseux, CEO and President at Cerenis Therapeutics. Filmed at the PharmaTelevision studios in Oxford, UK.

Silence Therapeutics boss appointed non-exec chairman of University of Oxford spin-out

Ali Mortazavi, the boss of gene silencing specialist Silence Therapeutics PLC (LON:SLN), has been appointed as the non-executive chairman of artificial intelligence and healthcare firm, Ultromics. Ultromics, which was spun out of the University of Oxford earlier this year, is a platform technology that extracts thousands of data points from a single image. It then uses machine learning, a form...

Military Medicine is now published by Oxford University Press

(Oxford University Press USA) Oxford University Press and AMSUS, the Society of Federal Health Professionals, are pleased to announce their new partnership to publish Military Medicine, the AMSUS bi-monthly scientific journal.

The last survivors on Earth

(University of Oxford) The world's most indestructible species, the tardigrade, an eight-legged micro-animal, also known as the water bear, will survive until the sun dies, according to a new Oxford University collaboration.

BioArt and Bacteria Exhibition is Coming to Oxford

A new exhibition in Oxford features the beautiful art of Anna Dumitriu, exploring the complex world of microbes and how we interact with them.  Anna Dumitriu, prolific bioartist that works with bacteria, will show some of her best work at ... This awesome article BioArt and Bacteria Exhibition is Coming to Oxford appeared first on Be kind and don't copy it without asking ;)

Oxford Biotech Can Detect Breast Cancer Stages via Blood

Oxford BioDynamics has developed a blood biopsy called EpiSwitch to test for breast cancer and its stages through epigenetic biomarkers. EpiSwitch, a liquid biopsy from spinout Oxford BioDynamics, has been shown in a 136-patient trial to identify breast cancer via epigenetic ... This awesome article Oxford Biotech Can Detect Breast Cancer Stages via Blood appeared first on Be kind a...

Ground-breaking digital health deal agreed with Drayson Technologies

Drayson Technologies Limited has announced a five-year Strategic Research Agreement (SRA) with the University of Oxford and Oxford University Hospitals NHS Foundation Trust (OUH) in the field of digital health. Millions of NHS patients are set to benefit from the commercialisation of cutting edge technologies invented in Oxford, following the landmark licensing deal between Drayson ... Read more

Oxford research project wins digital award for Bashing the Bug!

An Oxford-based international online project to tackle antibiotic resistance has picked up a national health research award. BashTheBug, an initiative funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), brings together volunteers from all over the world to take part in the online research study, which has looked at hundreds ... Read more

Crohn's & Colitis Foundation and Oxford University Press enter into publishing partnership

(Oxford University Press USA) The Crohn's & Colitis Foundation and Oxford University Press announced today that they have entered into a new partnership to publish the Foundation's journal Inflammatory Bowels Diseases beginning in 2018.

Oxford University Press launches new journal, Insect Systematics and Diversity

(Oxford University Press USA) Oxford University Press and the Entomological Society of America (ESA) are pleased to announce the launch of a new journal, Insect Systematics and Diversity (ISD). With the publication of its first issue on Oct. 25, ISD joins ESA's portfolio of eight other journals. The journal is led by Co-Editors-in-Chief Dr. Sydney A. Cameron and Dr. James B. Whitfield, both profes...

Quick Search

News Quicklinks